Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (268)	4/12/2005 4:51:25 PM
From: tuck	Read Replies (1) \| Respond to of 802

Well, Erbitux is going to be a little later than expected: Message 21221748 So R&R's call isn't looking quite so great just now. Cheers, Tuck

To: zeta1961 who wrote (268)	4/12/2005 8:36:57 PM
From: Ian@SI	Read Replies (1) \| Respond to of 802

Here's the full clip from Briefing. The other one left out the last couple sentences... ++++++++++ Introgen (INGN) : Rodman & Renshaw downgrades Mkt Perform to MKT UNDERPERFORM . With pending filings of Taxotere and Erbitux for locally advanced SCCHN, firm believes SCCHN may no longer be regarded as a critically unmet medical need. They remain doubtful that INGN's accelerated approval request to the FDA can be granted. Even if the request is granted, they are not convinced the FDA would approve a therapy based on retrospective analyses of subpopulation data. Should the request be denied or accelerated approval be rejected, they believe INGN shares could suffer a serious setback.